Terms: = Ovarian cancer AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025 AND Treatment
7 results:
1. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
2. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract] [Full Text] [Related]
4. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
Stevens EV; Raffeld M; Espina V; Kristensen GB; Trope' CG; Kohn EC; Davidson B
Cancer; 2005 Jun; 103(11):2313-9. PubMed ID: 15844177
[TBL] [Abstract] [Full Text] [Related]
5. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract] [Full Text] [Related]
6. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract] [Full Text] [Related]
7. Enhanced xpa mRNA levels in cisplatin-resistant human ovarian cancer are not associated with xpa mutations or gene amplification.
States JC; Reed E
Cancer Lett; 1996 Nov; 108(2):233-7. PubMed ID: 8973600
[TBL] [Abstract] [Full Text] [Related]
